本帖最后由 老马 于 2012-1-13 21:20 编辑 5 k- V: y3 A5 h
% @, }9 D$ f5 D5 K+ w
爱必妥和阿瓦斯丁的比较6 G6 k7 D9 ]. O4 d
; }( z: d+ @3 }: O8 }3 Y3 rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- F) L" J2 z s9 k/ C5 Y
6 i3 r/ y- T5 h2 _
% u" K' C4 i5 |+ vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' R# e! l, H, P% a
==================================================+ d1 ` D- X& {. A
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* i% o' @& @" n2 R6 d2 J& u- c' sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( K+ q1 ^0 @# DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: V5 \0 i: Y4 r" _
|
30岁教师确诊肺癌后逆袭：手术后，我
讲述者：范菇娘整理者：pear编者按“用实力坚持到胜利”ALK阳性非小细胞肺癌患者摄影
求助：1a1实体型低分化alk突变复发概
背景：35岁男性，无吸烟史，有熬夜习惯，检查前曾参与新房装修。24年7月底体检第一次
求助：肺腺癌晚期，奥希30个月耐药，
父亲65岁：
23年1月份：持续咳嗽，医院CT后，左肺大量胸腔积液，确诊肺腺癌晚期，胸膜
母亲晚期肺癌跨越13年，这是我家长期
讲述者：不怕辣椒不怕癌整理者：雪漓
在我家抗癌跨越10年之际，鹰版就曾邀请我写一篇
非小细胞肺腺癌四期骨转脑转肝转
非小细胞肺腺癌四期骨转脑转肝转，基因突变KRAS PG-12D，四线治疗安罗替尼耐药，目前
显身卡
5 |- k9 u6 H* T2 F. ^8 R0 _7 E* P1 Z
